Pegasys
+ Copegus
peginterferon
alfa-2a + Copegus (ribavirin) 
PEGASYS
Medication Guide
Pegasys
Product Information
Copegus
Medication Guide
Copegus
Product Information
|
 Articles
on Pegasys + Copegus |
• | Detectable HCV RNA at Week
8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with
Pegylated Interferon plus Ribavirin
6-23-2009 |
| • | Effectiveness of Pegylated Interferon plus Ribavirin
for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009 |
| • | IDEAL
Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated
Interferon plus Ribavirin Is Associated with Better Response
5/22/09 |
| • | Extended
72-week Treatment with Pegylated Interferon plus Ribavirin
Did Not Improve Outcomes among Slow Responder Hepatitis C Patients
5/08/09 |
| • | Early
Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy
Produces Better Results than Delayed Combination Therapy
5/05/09 |
| • | Adding
Telaprevir Improves Sustained Response to Pegylated Interferon
plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/05/09 |
| • | Experimental
HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears
Safe and Exhibits Good Antiviral Activity
5/05/09 |
| • | HIV
Positive and Negative Individuals with Acute or Early Chronic Hepatitis C Respond
Well to 24 Weeks of Pegylated Interferon plus Ribavirin
4/10/09 |
| • | Pegylated Interferon alfa-2a (Pegasys)
Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based
Ribavirin Dosage
4/07/09 |
| • | Overview
of the Current Standard of Care for Treatment
of Chronic Hepatitis C
4/03/09 |
| • | Phase
1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin
2/27/2009 |
| • | Extended
Pegylated Interferon plus Ribavirin Therapy
Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009 |
| • | Adherence
to Pegylated Interferon/ribavirin Therapy for
Hepatitis C and Early Treatment Response
1/30/2009 |
| | Combination
of Virus and Host Factors Predict Virological Response to Pegylated
Interferon plus Ribavirin for Chronic Hepatitis C
1/27/2009 |
| • | SAMe
Improves Early Response to Pegylated Interferon/ribavirin in
Small Study
12/12/2008 |
| • | Long-term
Low-dose Pegylated Interferon May Improve Liver
Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders
12/08/2008
|
| • | Results of the IDEAL Study of Treatment
of African Americans with Chronic Hepatitis C: A Slide Set Review
12/082008 |
| • | Nitazoxanide
Enhances Anti-HCV Activity of Pegylated interferon/ribavirin
and STAT-C Agents
12/02/2008
|
| • | Nitazoxanide
Enhances Anti-HCV Activity of Pegylated interferon/ribavirin
and STAT-C Agents
12/02/2008
|
| • | Extended
Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers
11/25/2008
|
| • | Canadian
POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated
Interferon plus Ribavirin
11/21/2008 |
| • | Genotype
1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of
Pegylated Interferon plus Ribavirin
11/18/2008 |
| • | IDEAL
Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin,
including Race/ethnicity and Anemia
11/07/2008
|
| • | Extended
Duration Pegylated Interferon/ribavirin for
Prior Non-responders and Relapsers
11/25/2008 |
| • | IDEAL
Researchers Look at Predictors of Response to Pegylated
Interferon plus Ribavirin, including Race/ethnicity and Anemia
11/07/2008 |
• | Safety and antiviral activity of BI 201335,
a new HCV NS3 protease inhibitor, in treatment-naïve patients with chronic hepatitis
C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R)
11/05/2008 |
• | Safety and antiviral activity of BI 201335,
a new HCV NS3 protease inhibitor, in combination therapy with peginterferon
alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced
patients with chronic hepatitis C genotype 1 infection
11/05/2008 |
• | Hematologic
Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles
of Peginterferon alfa/Ribavirin
11/05/2008 |
• | Treatment-Related
Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon
(PEG)/Ribavirin (RBV): Results From the IDEAL Study
11/05/2008 |
• | Response
to Pegylated Interferon plus Ribavirin in Asian
Patients with Genotype 1 Chronic Hepatitis C
10/21/2008 |
• | Pegylated Interferon plus Ribavirin
Produces High Sustained Response Rate in HBV-HCV Coinfected Individuals
10/17/08 |
• | 24
Weeks of Pegylated Interferon plus Ribavirin
May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with
Rapid Response
10/14/08 |
• | Individuals
with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin
10/14/08 |
• | Higher
Doses of Pegylated Interferon and Ribavirin
May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis
C
10/10/08 |
• | Sustained
Virological Response to Pegylated Interferon plus Ribavirin
for Chronic Hepatitis C Does Not Always Prevent Hepatocellular
Carcinoma
10/10/08 |
• | Genetic
Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C
Trial
9/09/2008 |
• | Insulin-sensitizing
Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment with Pegylated
Interferon plus Ribavirin
8/29/2008 |
• | Are
HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment
with Pegylated Interferon plus Ribavirin
8/19/2008 |
• | Body
Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated
with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin
8/12/2008 |
• | Eight
Weeks of Pegylated Interferon plus Ribavirin
for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR)
8/05/2008 |
• | Telaprevir
plus Pegylated Interferon and Ribavirin
Produces Rapid Response and Is Well Tolerated in 28-day Study
7/22/08 |
• | Comparison
of the Pegylated Interferons Pegasys and PegIntron
for Treatment of Chronic Hepatitis C: Analysis of 16 Randomized Trials
7/18/08 |
• | 12-
Versus 24-week Treatment with Pegylated Interferon plus
Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients
7/11/08 |
• | Studies
Explore Lower Doses of Pegylated Interferon and Ribavirin
for People with Hepatitis C Virus Genotypes 2 or 3
7/08/08 |
• | European
Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid
Responders with HCV Genotypes 2 or 3 and Low Viral Load
7/04/08 |
• | Pegylated
Interferon Alfa-2a (Pegasys) Continues to Suppress HBV, but Adding
Adefovir (Hepsera) Provides No Extra Benefit in PEG for B Trial
6/03/08 |
• | Platelet
Count Is a Strong Predictor of Sustained Response to Pegylated Interferon/ribavirin in
Prior Non-Responders (EPIC 3)
5/20/08 |
• | Rapid Virologic Response to Peginterferon
alfa and Ribavirin Treatment of Chronic Hepatitis C Predicts Sustained
Virologic Response and Relapse
5/20/08
|
• | Amino
Acid Substitutions in HCV Core Region Predict Poor Response to Pegylated
Interferon/ribavirin in Genotype 1b Patients
5/20/08 |
• | Pegylated Interferon plus Ribavirin
Is Effective for Patients with HCV-HBV Coinfection
5/09/08
|
• | Factors
Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated
Interferon plus Ribavirin
5/06/08 |
• | How
Ideal Is the IDEAL Trial?
|
FDA-approved
Combination Therapies for Chronic HCV Infection
